Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?

Have you been keeping an eye on Immunome, Inc. (IMNM) and wondering who's investing in this clinical-stage biotechnology company? As of April 2025, several institutional investors hold significant positions in Immunome. Are you curious about the shifts in ownership and what's driving these investment decisions? In 2024, Immunome's revenue was reported at $9.04 million, a -35.50% decrease compared to the previous year's $14.02 million, with losses of -$292.96 million, a 174.3% increase from 2023. Let's delve into the details of Immunome's investor profile, exploring the major shareholders and the factors influencing their investment strategies.

Immunome, Inc. (IMNM) Who Invests in Immunome, Inc. (IMNM) and Why?

Understanding the investor profile of Immunome, Inc. (IMNM) provides valuable insights into market sentiment and the potential drivers behind the stock's performance. A diverse investor base can contribute to price stability, while concentrated ownership may amplify volatility. Here's a breakdown of the key investor types, their motivations, and typical strategies.

Key Investor Types:

Immunome, Inc.'s (IMNM) ownership is distributed among institutional, retail, and individual investors.

• Institutional Investors: These entities, such as mutual funds, hedge funds, and pension funds, represent a significant portion of Immunome, Inc.'s (IMNM) shareholder base. As of recent filings, institutional investors hold a substantial number of Immunome, Inc. (IMNM) shares.
• Retail Investors: Individual investors also hold a stake in Immunome, Inc. (IMNM). The sentiment among Indian investors towards Immunome, Inc. (IMNM) has seen a 160% increase in search interest over the last 30 days.

As of recent data, the company has 264 institutional owners and shareholders with a total of 61,038,159 shares. The ownership structure of Immunome Inc. (IMNM) reveals that approximately 43.51% of the company's stock is held by institutional investors, 1.46% by insiders, and 9.43% by public companies and individual investors.

Here's a list of the top institutional shareholders:

• T. Rowe Price Investment Management, Inc.
• Redmile Group, LLC
• BlackRock, Inc.
• Fmr Llc
• EcoR1 Capital, LLC
• Enavate Sciences GP, LLC
• Janus Henderson Group Plc
• POAGX - PRIMECAP Odyssey Aggressive Growth Fund
• Vanguard Group Inc
• Price T Rowe Associates Inc /md/

Investment Motivations:

Several factors attract investors to Immunome, Inc. (IMNM):

• Growth Prospects: Immunome, Inc. (IMNM) operates in the biotechnology sector, which offers substantial growth potential. The company's focus on developing targeted cancer therapies and a novel approach to antibody discovery may attract investors seeking high-growth opportunities.
• Pipeline Expansion: Immunome, Inc.'s (IMNM) strategic pipeline expansion, especially after the merger with Morphimmune, presents a compelling investment opportunity. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets.
• Bullish Outlook: The put/call ratio of IMNM is 0.23, indicating a bullish outlook.
• Analyst Recommendations: Recent analyst ratings contribute to investor confidence. For example, Lake Street initiated coverage of Immunome, Inc. (IMNM) with a Buy recommendation.

Immunome, Inc. had cash, cash equivalents, and marketable securities of $217.3 million as of December 31, 2024. The company raised an additional $172.5 million in January 2025, bringing the total cash balance to $390 million.

Investment Strategies:

Investors in Immunome, Inc. (IMNM) may employ various strategies, depending on their investment goals and risk tolerance:

• Long-Term Holding: Investors with a long-term focus may hold Immunome, Inc. (IMNM) shares, anticipating significant returns from the company's clinical development programs and potential market entry.
• Short-Term Trading: Given the volatility often associated with biotechnology stocks, some investors may engage in short-term trading strategies to capitalize on price fluctuations.
• Value Investing: Value investors may see Immunome, Inc. (IMNM) as undervalued, particularly given its unique approach to antibody discovery and strategic pipeline expansion.

Here is a summary of key financial data and analyst sentiment:

Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts.

For more insights into Immunome, Inc.'s (IMNM) mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM).

Immunome, Inc. (IMNM) Institutional Ownership and Major Shareholders of Immunome, Inc. (IMNM)

Institutional ownership in Immunome, Inc. (IMNM) provides insights into the confidence and investment strategies of large financial entities. Examining the major shareholders and their recent activities can reveal trends and potential impacts on the company’s stock performance.

Here's an overview of Immunome, Inc.'s institutional ownership profile:

• Vanguard Group Inc.: As of March 31, 2024, Vanguard Group Inc. holds 1,398,898 shares, representing 11.98% ownership.
• BlackRock Fund Advisors: BlackRock Fund Advisors reported holding 624,417 shares as of March 31, 2024, accounting for 5.349% of the company's shares.
• State Street Global Advisors, Inc.: According to the latest filings, State Street Global Advisors, Inc. owns 341,756 shares as of March 31, 2024, which translates to 2.928% ownership.

The table below summarizes the shareholdings of some of the largest institutional investors in Immunome, Inc. (IMNM) as of March 31, 2024:

Changes in institutional ownership can indicate shifts in sentiment towards Immunome, Inc. (IMNM). Recent transactions and filings provide a glimpse into these changes:

• Increase in holdings: Citadel Advisors LLC increased its holdings by 28,844 shares in the 4th quarter of 2023.
• Decrease in holdings: Morgan Stanley reduced its position by 7.4% in the third quarter, selling 8,580 shares.

These changes reflect ongoing evaluations of Immunome, Inc.'s (IMNM) prospects and alignment with the investment strategies of these institutions.

Institutional investors often play a crucial role in shaping a company's stock price and influencing its strategic direction. Their substantial holdings can lead to:

• Price Stability: Large institutional positions can reduce volatility due to their long-term investment horizons.
• Corporate Governance: These investors can influence corporate governance through voting rights and engagement with company management.
• Market Perception: Institutional endorsements can enhance market confidence and attract further investment.

Understanding the dynamics of institutional ownership provides valuable context for investors and stakeholders interested in Immunome, Inc. (IMNM). For additional details, you might find this resource helpful: Immunome, Inc. (IMNM): History, Ownership, Mission, How It Works & Makes Money.

Immunome, Inc. (IMNM) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Immunome, Inc. (IMNM) provides crucial insights into the company's stability, growth potential, and strategic direction. Examining who is investing, their investment size, and their recent activities can reveal a great deal about market sentiment and future prospects for Immunome, Inc. (IMNM).

While specific, up-to-the-minute details on all Immunome, Inc. (IMNM) investors are subject to constant change, we can explore the types of investors typically interested in biotechnology companies like Immunome, Inc. (IMNM), and the impact they might have.

Here are potential categories of investors and their possible influence:

• Institutional Investors: These include mutual funds, pension funds, hedge funds, and insurance companies. Institutional investors often hold significant stakes in companies, and their trading activity can influence stock prices. Their investment decisions are usually based on extensive research and analysis.
• Venture Capital and Private Equity Firms: Biotech companies, especially during their early stages, often rely on venture capital for funding. These firms can provide not only capital but also valuable expertise and connections.
• Individual Investors: These can range from retail investors to high-net-worth individuals. Their impact varies depending on the size of their investments and their trading behavior.
• Strategic Investors: These are typically other companies in the pharmaceutical or biotechnology industries that invest in Immunome, Inc. (IMNM) for strategic reasons, such as access to new technologies or markets.

The influence of these investors can manifest in several ways:

• Stock Price Volatility: Large purchases or sales by institutional investors can cause significant fluctuations in Immunome, Inc. (IMNM)'s stock price.
• Corporate Governance: Major shareholders can influence decisions made by Immunome, Inc. (IMNM)'s management team, including strategic direction, executive compensation, and mergers and acquisitions.
• Access to Capital: The presence of well-known and respected investors can make it easier for Immunome, Inc. (IMNM) to raise additional capital in the future.
• Market Sentiment: Investor interest can serve as a signal to the broader market about the potential of Immunome, Inc. (IMNM)'s pipeline and technology.

To gain a clearer picture of investor activity, one can monitor:

• SEC Filings: Reviewing filings such as 13D and 13G can reveal who the major shareholders are and whether they have been increasing or decreasing their positions.
• Earnings Calls and Investor Presentations: These events often provide insights into management's perspective on investor relations and any notable changes in the shareholder base.
• News Articles and Financial Reports: Keep an eye on reputable financial news outlets for reports on significant investor activity or opinions regarding Immunome, Inc. (IMNM).

Keeping tabs on these areas offers a comprehensive understanding of the investor landscape surrounding Immunome, Inc. (IMNM), and how these investors may shape the company's future.

To further enrich your understanding of Immunome, Inc. (IMNM), consider exploring the Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM).

Immunome, Inc. (IMNM) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Immunome, Inc. (IMNM) is crucial for assessing the company's current standing and future prospects. Recent trading activities and ownership changes can significantly influence stock performance and overall market perception.

Major shareholders' sentiment towards Immunome, Inc. (IMNM) plays a vital role in shaping investor confidence. While specific sentiment details (positive, neutral, or negative) require real-time monitoring of investor communications and filings, observing significant changes in holdings can offer clues. For instance, increased buying activity by institutional investors might indicate a positive outlook, whereas large sell-offs could suggest concerns about the company's performance or future prospects.

Recent market reactions to Immunome, Inc. (IMNM) stock often correlate with significant ownership changes or large investor moves. Positive news, such as a major institutional investor increasing their stake, typically leads to a stock price increase. Conversely, news of a large investor reducing their position can result in a price decline. Analyzing these market reactions provides insights into how the investment community values Immunome, Inc. (IMNM)'s potential and manages risk.

Analyst perspectives on Immunome, Inc. (IMNM) often highlight the impact of key investors on the company’s future. Analysts consider the expertise, resources, and potential influence that major shareholders bring to the table. For example, a prominent healthcare-focused investment firm taking a significant stake might signal confidence in Immunome, Inc. (IMNM)’s technology and market strategy. Analyst reports typically assess how these investments could drive innovation, market expansion, and ultimately, shareholder value.

To provide a clearer picture, consider the following aspects of investor impact:

• Market Confidence: Major investors' actions can significantly boost or diminish market confidence in Immunome, Inc. (IMNM).
• Stock Volatility: Large trades by institutional investors can lead to increased stock price volatility.
• Long-Term Strategy: Key investors often influence the company's strategic decisions, particularly in research and development and market expansion.
• Financial Stability: Substantial investments can provide Immunome, Inc. (IMNM) with the financial resources needed to pursue its clinical programs and growth initiatives.

For more detailed information on Immunome, Inc.'s background, mission, and ownership structure, refer to this comprehensive overview: Immunome, Inc. (IMNM): History, Ownership, Mission, How It Works & Makes Money

While specific real-time data on investor sentiment and recent market reactions require up-to-the-minute financial analysis, understanding these general principles is essential for any investor or stakeholder in Immunome, Inc. (IMNM).